Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Govindan, Ramaswamy, Aggarwal, Charu, Antonia, Scott J, Davies, Marianne, Dubinett, Steven M, Ferris, Andrea, Forde, Patrick M, Garon, Edward B, Goldberg, Sarah B, Hassan, Raffit, Hellmann, Matthew D, Hirsch, Fred R, Johnson, Melissa L, Malik, Shakun, Morgensztern, Daniel, Neal, Joel W, Patel, Jyoti D, Rimm, David L, Sagorsky, Sarah, Schwartz, Lawrence H, Sepesi, Boris, Herbst, Roy S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157337/
https://www.ncbi.nlm.nih.gov/pubmed/35640927
http://dx.doi.org/10.1136/jitc-2021-003956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157337/
https://www.ncbi.nlm.nih.gov/pubmed/35640927
http://dx.doi.org/10.1136/jitc-2021-003956

Ejemplares similares